This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Cookies Policy.


HER2 targeting is an opportunity3,4

HER2 overexpression and/or amplification is an oncogenic driver in multiple tumor types, as well as a potential therapeutic target.

HER2 positivity across select cancers5,6,7,8

HER2 overexpression and/or amplification graph showing HER2 positivity across select cancers

Discover the importance of testing for HER2 in mCRC.

Join our list of labs that test for HER2 in mCRC.

Learn more about the central role of HER2 in cancer

HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer.

References: 1. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97(4):453-457. 2. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264-275. 3. Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108-1119. 4. Ross JS, Ali SM, Elvin JA, et al. Targeted therapy for HER2 driven colorectal cancer. J Clin Oncol. 2017;35(15 suppl):3583-3583. 5. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010;376(9749):1302]. Lancet. 2010;376(9742):687-697. 6. Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17(10):594-604. 7. Kang A, Bloudek L, Mordi U, et al. Systematic literature review of HER2 amplification/overexpression in colorectal cancer. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 18-21, 2021; Denver, Colorado. 8. Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. JCO Precis Oncol. 2020;4:411-425